Skip to content
Screener

Oruka Therapeutics, Inc. ORKA Q4 2024 Annual earnings

Reported March 6, 2025 · Before market open

EPS-$0.49Beat by $0.19
EPS estimate-$0.68

Next report

Aug 10, 2026 (Tomorrow)
EPS estimate-$0.51

Financials

Q4 2024

Income statement

See full
Operating income-$88.1M-5,442%
Net income-$83.7M-7,588%
EPS (diluted)-$3.87-4,737%

Balance sheet

See full
Cash & equivalents$61.6M+64.5%
Total debt$968.0K+246%
Total equity$382.2M+932%
Total assets$396.0M+946%

Cash flow

See full
Operating cash flow-$57.8M-5,377%
CapEx$189.0K—
Free cash flow-$58.0M-4,529%

Valuation & ratios

Valuation

as of 12/31/24
See full
Market cap$678.62M—
Enterprise value$618.01M—

Returns & leverage

See full
Return on equity-67.6%-90.3pp
Debt / equity0×0.0×
Current ratio28.9×-30.1×

FAQ

When did Oruka Therapeutics, Inc. report Q4 2024 earnings?
Oruka Therapeutics, Inc. (ORKA) reported Q4 2024 earnings on March 6, 2025 before market open.
What were Oruka Therapeutics, Inc.'s Q4 2024 revenue and EPS?
Oruka Therapeutics, Inc. reported eps of $-0.49 for Q4 2024.
Did Oruka Therapeutics, Inc. beat estimates in Q4 2024?
EPS beat the consensus estimate of $-0.68 by $0.19.
Where can I find Oruka Therapeutics, Inc.'s Q4 2024 SEC filings?
You can read the 10-K periodic report (0001213900-25-021165) directly on SEC EDGAR. The filing index links above go to sec.gov.